Related Experiment Videos
Risk factors for second malignant neoplasms: report from the Late Effects Study Group
1Children's Hospital of Philadelphia, PA 19104.
Bulletin Du Cancer
|January 1, 1988
Summary
Children treated for childhood cancer have an 8% risk of developing a second malignant neoplasm (SMN) within 20 years. Treatments like radiation therapy and alkylating agents, along with genetic factors, increase this risk.
Area of Science:
- Pediatric Oncology
- Cancer Epidemiology
- Clinical Genetics
Background:
- Childhood cancer survivors face increased risks of long-term health issues.
- Second malignant neoplasms (SMN) represent a significant late effect of cancer treatment.
- Understanding risk factors for SMN is crucial for improving long-term outcomes in survivors.
Purpose of the Study:
- To analyze the incidence and characteristics of SMN in a large cohort of childhood cancer patients.
- To identify specific primary cancers and treatments associated with increased SMN risk.
- To evaluate the role of genetic predisposition in SMN development.
Main Methods:
- Retrospective analysis of 368 cases of SMN from the Late Effects Study Group (LESG) database.
- Review of primary diagnoses, treatments (radiation therapy, alkylating agents), and SMN types.
- Calculation of SMN incidence based on follow-up duration and patient cohorts.
Main Results:
- The most common first neoplasms were retinoblastoma and Hodgkin's disease.
- Sarcomas were the most frequent SMN, often linked to radiation therapy.
- Leukemias were frequently observed, associated with alkylating agent use.
- The 20-year incidence of SMN was 8% in recent LESG data.
Conclusions:
- Childhood cancer survivors have a substantially elevated risk of developing SMN.
- Treatment modalities, particularly radiation and alkylating agents, are key contributors to SMN.
- Genetic predisposition may further augment the risk of secondary malignancies.